Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head ...

An expert discusses practical strategies for assessing atopic dermatitis severity, highlighting simple yet effective tools such as the Investigator Global Assessment (IGA) scale, palm-based body ...

Richard Auchus, MD, PhD, highlights data showing that crinecerfont use in children with CAH can improve metabolic outcomes.

An expert discusses the benefits and risks of topical corticosteroids (TCS) and calcineurin inhibitors in atopic dermatitis (AD) treatment, highlighting patient concerns about long-term adverse ...

An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of ...

Elizabeth Reichert, PhD, shared practical tips for pediatricians to help families monitor teen media use and recognize early signs of anxiety.

An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar ...

The FDA approved concizumab-mtci (Alhemo; Novo Nordisk) for hemophilia A/B without inhibitors, offering once-daily subcutaneous prophylaxis that significantly reduces bleeding rates.

On July 30, 2025, AbbVie announced positive and topline data from the phase 3 UP-AA clinical program (NCT06012240), in which upadacitinib (Rinvoq) (15 mg and 30 mg) demonstrated that 44.6% and 54.3% ...

On July 28, 2025, the FDA approved PTC Therapeutics' sepiapterin (Sephience) to treat adult and pediatric patients with phenylketonuria (PKU), including all age groups and the full spectrum of disease ...

On July 28, 2025, the FDA approved PTC Therapeutics' sepiapterin (Sephience) to treat adult and pediatric patients with phenylketonuria (PKU). Sepiapterin is now the third FDA-approved medication for ...